It is estimated that over 11,000 children across Europe, Middle East, and Africa are affected by achondroplasia and could be eligible for treatment with Voxzogo
Roche is notifying healthcare professionals and patients in the US about this withdrawal. Patients being treated with Tecentriq for PD-L1-positive mTNBC should discuss their care with their healthcare provider
The manufacture of finished doses will commence in 2022 and at full operational capacity, the annual production is expected to exceed 100 million doses annually
First results demonstrate favourable tolerability of TQL-1055 at all dose levels
The company to receive upfront and milestone payments, in addition to royalties
The Evolut FX TAVR system is used for treatment of symptomatic severe aortic stenosis and it has features that enhance ease-of-use and predictable valve deployment
The agreement is to develop, manufacture and commercialise biosimilars for the global market.
The aim is to give a fillip to R&D in the health sector to face the Covid-19 challenge
Trillium’s portfolio includes biologics that are designed to enhance the ability of patients’ innate immune system to detect and destroy cancer cells
This year, the company plans to set up more than 200 labs and 3000 collection centres across the world and has ended FY 21 with a revenue of Rs 800 crores
Subscribe To Our Newsletter & Stay Updated
